Inhibition of PCSK9 significantly reduced myocardial fibrosis post-myocardial infarction as demonstrated by echocardiographic and Masson staining results.
Does PCSK9 knockout reduce myocardial fibrosis and improve cardiac function after myocardial infarction in a mouse model?
PCSK9 promotes myocardial fibrosis after myocardial infarction by inducing platelet activation and TGF-β secretion, providing a novel mechanistic rationale for PCSK9 inhibition in post-MI cardiac repair.
Absolute Event Rate: 0% vs 0%
Aims The recovery of cardiac function after acute myocardial infarction is crucial for the prognosis of patients with myocardial infarction. Proprotein convertase subtilisin/Kexin Type 9 (PCSK9) inhibitors are widely used in patients with acute myocardial infarction due to their potent low‐density lipoprotein‐lowering effects. Recent studies have shown that elevated levels of circulating PCSK9 are associated with increased platelet reactivity and thrombosis; however, the effect and mechanism of PCSK9 on cardiac repair after myocardial infarction through the induction of platelet activation remain unclear. Therefore, the objective of this study was to investigate and clarify the specific effect of PCSK9 on cardiac repair processes following myocardial infarction. The detailed molecular and cellular mechanisms through which PCSK9 regulates cardiac repair after myocardial infarction by inducing platelet activation were observed. Methods and Results Hearts from wild‐type (WT) C57BL/6J mice and PCSK9 knockout (PCSK9 − / − ) mice were subjected to left coronary artery (LAD) ligation to establish a myocardial infarction model. Six weeks postoperation, echocardiographic analysis and Masson staining revealed that inhibiting the increase in PCSK9 expression after myocardial infarction significantly reduced myocardial fibrosis. Transcriptome sequencing of mouse myocardial tissue suggested that PCSK9 suppresses immune regulation and adhesion pathways and that the platelet marker integrin subunit alpha 2b (Itga2b) is a potential key molecule. Subsequent in vivo and in vitro experiments demonstrated that PCSK9 promotes platelet activation and induces the fibrogenic phenotypic transformation of fibroblasts by transforming growth factor‐ β (TGF‐ β ). In further studies, coculture experiments of fibroblasts and platelets revealed that PCSK9 promotes the conversion of fibroblasts to myofibroblasts by inducing platelet‐derived TGF‐ β secretion. Conclusion PCSK9 promotes platelet activation, induces the secretion of platelet‐derived TGF‐ β , and thereby accelerates myocardial fibrosis after myocardial infarction.
Wang et al. (Thu,) reported a other. Inhibition of PCSK9 significantly reduced myocardial fibrosis post-myocardial infarction as demonstrated by echocardiographic and Masson staining results.